In light of the latest news regarding the DEA’s telehealth regulations and the closing of two renowned ketamine clinics with facilities in the U.S., Benzinga had the opportunity to interview Jay Godfrey, co-founder of the NYC-based ketamine-assisted therapy center Nushama.
This is the second article of a three-part series, you can find the first story of the series here.
When Benzinga asked whether Nushama is considering entering the telehealth space, Godfrey says the short answer is no.
“The intermediate answer is: Research thus far has shown that the greatest efficacy and safety is achieved under medical supervision in-clinic. End of story,” he said.
Nushama's protocol works for in-clinic ketamine therapy. Offered for people with a variety of mood disorders, the most common causes that take people to the center are depression and anxiety.
Further, the recent partnership with major psychedelics company Awakn Life Sciences (OTC: AWKNF) gives Nushama an NYC-exclusive license to the very successful KARE protocol designed for the treatment of Alcohol Use Disorder (AUD) with which it has begun dosing the first patient last week.
Nushama’s viewpoint is that all of these indications are sourced from unresolved trauma, acting as symptoms of the condition. “Ultimately, what is different about this particular type of treatment and work, is that we are addressing the underlying issue and the underlying trauma,” Godfrey told Benzinga.
With 70% to 80% of patients showing significant improvement, what separates Nushama from many other clinics, says Godfrey, is that they offer integration. He added that the therapy component is a necessity. “Ten percent of it is related to the actual molecule, …